- Home
- URGN vs FCAP Comparison
URGN vs FCAP Comparison
Compare URGN & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FCAP
- Stock Information
- Founded
- URGN 2004
- FCAP 1891
- Country
- URGN United States
- FCAP United States
- Employees
- URGN N/A
- FCAP N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FCAP Savings Institutions
- Sector
- URGN Health Care
- FCAP Finance
- Exchange
- URGN Nasdaq
- FCAP Nasdaq
- Market Cap
- URGN 181.2M
- FCAP 161.2M
- IPO Year
- URGN 2017
- FCAP 1999
- Fundamental
- Price
- URGN $13.84
- FCAP $43.69
- Analyst Decision
- URGN Strong Buy
- FCAP
- Analyst Count
- URGN 8
- FCAP 0
- Target Price
- URGN $29.00
- FCAP N/A
- AVG Volume (30 Days)
- URGN 4.3M
- FCAP 31.3K
- Earning Date
- URGN 08-12-2025
- FCAP 07-25-2025
- Dividend Yield
- URGN N/A
- FCAP 2.69%
- EPS Growth
- URGN N/A
- FCAP 2.61
- EPS
- URGN N/A
- FCAP 3.65
- Revenue
- URGN $91,871,000.00
- FCAP $42,869,000.00
- Revenue This Year
- URGN $36.65
- FCAP N/A
- Revenue Next Year
- URGN $88.35
- FCAP N/A
- P/E Ratio
- URGN N/A
- FCAP $11.80
- Revenue Growth
- URGN 8.98
- FCAP 6.35
- 52 Week Low
- URGN $3.42
- FCAP $28.50
- 52 Week High
- URGN $18.15
- FCAP $53.85
- Technical
- Relative Strength Index (RSI)
- URGN 64.90
- FCAP 49.16
- Support Level
- URGN $13.26
- FCAP $42.70
- Resistance Level
- URGN $13.94
- FCAP $44.23
- Average True Range (ATR)
- URGN 0.91
- FCAP 1.75
- MACD
- URGN -0.08
- FCAP 0.22
- Stochastic Oscillator
- URGN 44.44
- FCAP 79.82
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.